Sonic Incytes company
Sonic Incytes is a medical device start-up company developing quantitative ultrasound for point-of-care diagnostic and procedure guidance. With core software that uses traditional ultrasound equipment to quantify physical properties of tissue, we enable earlier disease detection and more reliable monitoring for chronic illness. Our first pursued market application is the early detection of liver disease primarily caused by metabolic syndrome. We aid in the management of liver disease and improve overall metabolic health and wellness. Sonic Incytes had its beginnings at the University of British Columbia and is led by an experienced team with demonstrated expertise in building successful companies and bringing forth medical technology to market. The leadership team brings extensive knowledge of medtech entrepreneurship, ultrasound & medical imaging, AI machine learning, liver disease, metabolic health & U.S. healthcare. The team has cultivated strong relationships in both local and global centers of excellence in medical care and clinical research.